Treatment of concomitant illneses in patients receiving anticonvulsants. Drug interactions of clinical significance

Drug Safety

Volumn 19, Issue 6, 1998, Pages 495-510

  Loiseau, Pierre ^a,b  

^a University Hospital   (France)

^b NONE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED CARBON; ANALGESIC AGENT; ANTACID AGENT; ANTIASTHMATIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; ANTIULCER AGENT; BENZODIAZEPINE; CALCIUM ANTAGONIST; CARBAMAZEPINE; CONTRACEPTIVE AGENT; CYTOCHROME P450; DILTIAZEM; FELBAMATE; GABAPENTIN; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; LAMOTRIGINE; MACROLIDE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PSYCHOTROPIC AGENT; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL; VIGABATRIN; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; CARDIOVASCULAR AGENT; ORAL CONTRACEPTIVE AGENT;

ATAXIA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOXICITY; DRUG TRANSFORMATION; ENZYME INDUCTION; ENZYME INHIBITION; EPILEPSY; HUMAN; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; TREMOR; CASE REPORT; DRUG INTERACTION;

ANALGESICS; ANTI-ASTHMATIC AGENTS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ANTICONVULSANTS; ANTIFUNGAL AGENTS; CARDIOVASCULAR AGENTS; CONTRACEPTIVES, ORAL; DRUG INTERACTIONS; EPILEPSY; HUMANS; PSYCHOTROPIC DRUGS;

EID: 0032217079     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199819060-00006     Document Type: Review

References (191)

1. Pippenger CE. An overview of antiepileptic drug interactions. Epilepsia 1982; 23 Suppl. 2: 81-6
2. Kutt H. Interactions between anticonvulsants and other commonly prescribed drugs. Epilepsia 1984; 25 Suppl. 2: 118-31
3. Bourgeois BFD. Important pharmacokinetic properties of antiepileptic drugs. Epilepsia 1995; 36 Suppl. 5: 1-7
4. Neef C, de Voogd-van der Straaten I. An interaction between cytostatic and antiepileptic drugs. Clin Pharmacol Ther 1988; 43: 372-5
5. Hurwitz A. Antacid therapy and drug kinetics. Clin Pharmacokinet 1977; 2: 269-80
6. Neuvonen PJ, Elonen E. Effect of activated charcoal on absorption and elimination of phenobarbitone, carbamazepine and phenylbutazone in man. Eur J Clin Pharmacol 1980; 17: 51-7
7. Perucca E. Pharmacokinetic interactions with antiepileptic drugs. Clin Pharmacokinet 1982; 7: 7-84
8. Mattson RH. The role of the old and the new antiepileptic drugs in special populations: mental and multiple handicaps. Epilepsia 1996; 7 Suppl. 6: 45-53
9. McInnes GT, Brodic MJ. Drug interactions that matter: A critical reappraisal. Drugs 1988; 36: 83-110
10. Brodie MJ. Drug interactions in epilepsy. Epilepsia 1992; 33 Suppl. 1: 13-22
11. Patsalos PN, Duncan JS. Antiepileptic drugs: a review of clinically significant drug interactions. Drug Saf 1993; 9: 156-84
12. Pippenger CE. Clinically significant drug interactions: an overview. Epilepsia 1987; 28 Suppl 3: 71-6
13. Perucca E, Richens A. General principles. Biotransformation In: Levy R, Mattson R, Meldrum B, editors. Antiepileptic drugs, 4th ed. New York: Raven Press, 1995; 31-50
14. Levy RH, Kerr BM. Pharmacokinetics of old, new, and yet-to-be-discovered antiepileptic drugs. Epilepsia 1989; 30 Suppl. 1: 35-41
15. Vestal RE. Drug use in the elderly: a review of problems and special considerations. Drugs 1978; 16: 358-82
16. Parker BM, Cuzack BJ, Vestall RE. Pharmacokinetic optimisation of drug therapy in elderly patients. Drugs Aging 1995; 7: 10-8
17. Perucca E. Clinical significance of drug interactions in epilepsy: a changing scenery [abstract]. Epilepsia 1997; 38 Suppl. 3: 278
18. Mattson RH. Efficacy and adverse effects of established and new antiepileptic drugs. Epilepsia 1995; 36 Suppl. 2: 12-26
19. Levy RH. Cytochrome P450 isozymes and antiepileptic drug interactions. Epilepsia 1995; 36 Suppl. 5: 8-13
20. Levy RH. Rational approach to prediction of drug interactions among antiepileptic drugs [abstract]. Epilepsia 1997; 38 Suppl. 3: 278
21. Back DJ, Griminer SFM, Orme MLE, et al. Evaluation of Committee on Safely of Medicine yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics. Br J Clin Pharmacol 1988; 25: 527-32
22. Coulam CB, Annegers JF. Do anticonvulsants reduce the efficacy of oral contraceptives? Epilepsia 1979; 20: 519-26
23. Sonnen AEH. Sodium valproate and the contraceptive pill. Br J Clin Pract 1983; Suppl. 27: 31-5
24. MacDonald MG, Robinson DS. Clinical observations of possible barbiturate interference with anticoagulation. JAMA 1968; 204: 97-100
25. Hunt BA, Self TH, Lalonde RL, et al. Calcium channel blockers as inhibitors of drug metabolism. Chest 1989; 96: 393-9
26. Larkin JG, Buller E, Brodie MJ. Nifedipine for epilepsy?: a pilot study. BMJ 1988; 296: 530-1
27. Periti P, Mazzei T, Mini E, et al. Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 1992; 23: 106-31
28. Perucca E. The new generation of antiepileptic drugs: advantages and disadvantages. Br J Clin Pharmacol 1996; 42: 531-43
29. Perucca E, Bialer M. The clinical pharmacokinetics of the newer antiepileptic drugs: focus on topiramate, zonisamide and tiagabine. Clin Pharmacokinet 1996; 31: 29-46
30. Shorvon D. Clohazam. In: Levy R, Mattson R, Meldrum B, editors. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995; 763-77
31. Schmidt D. Diazepam. In: Levy R, Mattson R, Meldrum B, editors. Antiepileplic drugs. 4th ed. New York: Raven Press, 1995: 705-24
32. Homan RW, Treiman DM, Lorazepam. In: Levy R, Mattson R, Meldrum B, editors. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995: 779-90
33. Baruzzi A, Michelucci R, Tassinari CA. Nitrazepam. In: Levy R, Mattson R, Meldrum B. editors. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995: 735-49
34. Dam M, Christiansen J. Interaction of propoxyphene with carbamazepine [letter]. Lancet 1977; 2: 509
35. Stensgaard-Hansen BS, Dam M, Brandt S, et al. Influence of dextropropoxyphene on steady-state serum levels and protein-binding of three antiepileptic drugs. Acta Neurol Scand 1980; 61: 357-67
36. Dalton MJ, Powel JR, Messenheimer JA, et al. Cimetidine and carbamazepine: a complex drug interaction. Epilepsia 1996; 27: 533-8
37. Mesdjian E, Dravet C, Cenraud B, et al. Carbamazepine intoxication due to triacetyloleandomycin administration in epileptic patients. Epilepsia 1980; 21: 489-96
38. Hedrick R, Williams F, Morin R, et al. Carbamazepine-erythromycin interaction leading to carbamazepine toxicity in four epileptic children. Ther Drug Monit 1983; 5: 405-7
39. Loiseau P, Guyot M, Pautrizel B, et al. Intoxication par la carbamazepine due à l'interaction carbamazépine-érythromycine [letter]. Press Med 1985; 14: 162
40. Vincon G, Albin H, Demotes-Mainard F, et al. Effects of josamycin on carbamazepine kinetics. Eur J Clin Pharmacol 1987; 32: 321-3
41. Barzaghi N, Gatti G, Crema F, et al. Effect of flurithromycin, a new macrolide antibiotic, on carbamazepine disposition in normal subjects. Int J Clin Pharm Res 1988; 8: 101-5
42. Tinel M, Descatoire V, Larrey D, et al. Effects of clarithromycin on cytochrome P-450. Comparisons with other macrolides. J Pharmacol Exp Ther 1989; 250: 746-51
43. Couet W, Istin B, Ingrand I, et al. Effect of ponsinomycin on single-dose kinetics and metabolism of carbamazepine. Ther Drug Monitor 1990; 12: 144-9
44. Gascon MP, Dayer P. Comparative effects of macrolide antibiotics on liver monooxygenases. Clin Pharmacol Ther 1991; 49: 158
45. Zagnoni PG, DeLuca M, Casini A. Carbamazepine-miocamycin interaction [abstract]. Epilepsia 1991; 32 Suppl. 1: 28
46. Albani F, Riva R, Baruzzi A. Clarithromycin-carbamazepine interaction: a case report. Epilepsia 1993; 34: 161-2
47. Valsalan VC, Cooper GL. Carbamazepine intoxication caused by interaction with isoniazid [letter]. BMJ 1982; 285: 261-2
48. Wright JM, Stokes EF, Sweeeney VP. Isoniazid-induced carbamazepine toxicity and vice-versa. N Engl J Med 1982; 307: 1325-7
49. Brodie MJ, MacPhee GJA. Carbamazepine toxicity precipitated by diltiazem. BMJ 1986; 292: 1170-1
50. Bahls FH, Ozuna J, Ritchie DE. Interactions between calcium channel blockers and the anticonvulsants carbamazepine and phenytoin. Neurology 1991; 41: 740-2
51. MacPhee GJA, McInnes GT, Thompson GG, et al. Verapamil potentiates carbamazepine neurotoxicity: a clinically important inhibitory interaction. Lancet 1986; 1: 700-3
52. Pisani F, Narbone MC, Fazio A, et al Effect of viloxazine on serum carbamazepine levels in epileptic patients. Epilepsia 1984; 25: 482-5
53. Grimsley SR, Jann MW, Carter JG. et al. Increased carbamazepine plasma concentrations after fluoxetine administration. Clin Pharmacol Ther 1991; 50: 10-5
54. Gidal BE, Anderson GD, Seaton TL, et al. Evaluation of the effect of fluoxetine on the formation of carbamazepine epoxide. Ther Drug Monit 1993; 15: 405-9
55. Spina E, Avenoso A, Pollicino AM, et al. Carbamazepine coadministration with fluoxetine or fluvoxamine. Ther Drug Monit 1993; 15: 247-50
56. Martinelli V, Bochetta A, Palmas AM, et al. An interaction between carbamazepine and fluvoxamine. Br J Clin Pharmacol 1993; 36: 615-6
57. Krämer G, Theisohn M, von Unruh GE, et al. Carhamazepinedanazol interaction: its mechanism examined by a stable isotope technique. Ther Drug Monit 1986; 8: 387-92
58. Levy RH, Wurden CJ. Carbamazepine. Interactions with other drugs. In: Levy R, Mattson R, Meldrum B, editors. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995: 543-54
59. Kerr BM, Levy RH. Carbamazepine epoxide. In: Levy R, Mattson R, Meldrum B, editors. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995: 529-41
60. Pisani F, Haj-Yehia A, Fazio A, et al. Carbamazepinevalnoctamide interaction in epileptic patients: in vitrolin vivo correlation. Epilepsia 1993; 34: 954-90
61. Jonkman JHG, Upton RA. Pharmacokinetic drug interaction with theophylline. Clin Pharmacokinet 1984; 9: 309-34
62. Molholm Hansen J, Siersbaek-Nielsen K, Skovsted L. Carbamazepine-induced acceleration of diphenylhydantoin and warfarin metabolism in man. Clin Pharmacol Ther 1971; 12: 539-43
63. Penttilä O, Neuvonen PJ, Aho K, et al. Interaction between doxycycline and some antiepileptic drugs. BMJ 1974; 2: 470-2
64. Bittencourt PRM, Gracia CM, Martins R, et al. Phenytoin and carbamazepine decrease oral bioavailability of praziquantel. Neurology 1992; 42: 492-6
65. Backman JT, Olkkola KT, Ojala M, et al. Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. Epilepsia 1996; 37: 253-7
66. Brown CS, Wells BG, Cold JA, et al. Possible influence of carbamazepine on plasma imipramine concentrations in children with attention deficit disorder. J Clin Psychopharmacol 1990; 10: 359-62
67. Brosen K, Kragh-Sorensen P. Concomitant intake of nortriptyline and carbamazepine. Ther Drug Monit 1993; 15: 258-60
68. Kidron R, Auerhuch I, Klein E, et al. Carbamazepine-induced reduction of blood levels of haloperidol in chronic schizophrenia. Biol Psychiatry 1985; 20: 219-22
69. Arana GW, Goff DC, Friedman H, et al. Does carbamazepine-induced reduction of plasma haloperidol level worsen psychotic symptoms? Am J Psychiatry 1986; 143: 650-1
70. Raitasuo V, Lehtovaara R, Huttunen MO. Carbamazepine and plasma levels of clozapine. Am J Psychiatry 1993; 150: 169
71. Orme M. Oral contraceptive and anticonvulsant drugs. Br J Clin Pract 1983; Suppl. 21: 26-30
72. Bonay M, Joinille-Bera AP, Diot P, et al. Possible interaction between phenobarbital, carbamazepine, and itraconazole. Drug Saf 1993; 9: 309-11
73. Yee GC, McGuire TR. Pharmacokinetic drug interactions with cyclosporin (Pt 1). Clin Pharmacokinet 1990; 19: 314-32
74. Sachdeo RC, Sachdeo SK, Howard JR, et al. Effect of antacid on the absorption of felbamate in subjects with epilepsy [abstract]. Epilepsia 1993; 34 Suppl. 6: 79
75. Leppik IE. Felbamate. Epilepsia 1995; 36 Suppl. 2: 66-72
76. Banfield CR, Levy RH. Felbamate. Interactions with other drugs. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995: 813-6
77. McLean MJ. Gabapentin. Epilepsia 1995; 36 Suppl. 2: 73-86
78. Eldon MA, Underwood BA, Randinitis EJ, et al. Lack of effect of gabapentin on the pharmacokinetics of a norethindrone acetate/ethinyl estradiol-containing oral contraceptive. Neurology 1993; 43 Suppl. 2: 307A-8A
79. Rambeck B, Wolf P. Lamotrigine clinical pharmacokinetics. Clin Pharmacokinet 1993; 25: 433-43
80. Posner J, Webster H, Yuen WC. Investigation on the ability of lamotrigine, a novel antiepileptic drug, to induce mixed function oxygenase enzymes [abstract]. Br J Clin Pharmacol 1991; 32: 658P
81. Burstein AH. Lamotrigine. Pharmacotherapy 1995; 15: 129-43
82. Depot M, Powell JR, Messenheimer Jr JA, et al. Kinetic effects of multiple oral doses of acetaminophen on a single oral dose of lamotrigine. Clin Pharmacol Ther 1990; 48: 346-55
83. Holdich T, Whiteman P, Orme M, et al. Effect of lamotrigine on the pharmacology of the combined oral contraceptive pill [abstract]. Epilepsia 1991; 32 Suppl. 1: 96
84. Faigle JW, Menge GP. Pharmacokinetics and metabolic features of oxcarbazepine and their clinical significance: comparing with carbamazepine. Int Clin Psychopharmacol 1990; 5 Suppl. 1: 73-82
85. Mogensen PH, Jorgensen L, Boas J, et al. Effects of dextropropoxyphene on the steady-state kinetics of ovcarbazepine and its metabolites. Acta Neurol Scand 1992; 85: 14-7
86. Keränen T, Jolkkonen J, Jensen PK, et al. Absence of interaction between oxcarbazepine and erythromycin. Acta Neurol Scand 1992; 86: 120-3
87. Keränen T, Jolkkonen J, Klosterkov Jensen P, et al. Oxcarbazepine does not interact with cimetidine in healthy volunteers. Acta Neurol Scand 1992; 85: 239-42
88. Krämer G, Tettenborn B, Flesh G. Oxcarbamazepinc-verapamil drug interaction in healthy volunteers [abstract]. Epilepsia 1991; 32 Suppl. 1: 70
89. Pisani F, Oteri G, Russo M, et al. Double-blind, within-patient study to evaluate the influence of viloxazine on the steady-state plasma levels of oxcarbazepine and its metabolites [abstract]. Epilepsia 1991; 32 Suppl. 1: 70
90. Krämer G, Tettenborn B, Klosterkov Jensen P, et al. Oxcarbazepine does not affect the anticoagulant activity of warfarin. Epilepsia 1992; 33: 1145-8
91. Zaccara G, Gangemi PF, Bendoni L, et al. Influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine. Ther Drug Monit 1993; 15: 39-42
92. Klosterkov Jensen P, Saano V, Haring P, et al. Possible interaction between oxcarbazepine and an oral contraceptive. Epilepsia 1992; 33: 1149-52
93. Sonnen AEH. Oxcarbazepine and oral contraceptives. Acta Neurol Scand 1990; 82 Suppl. 133: 37
94. Baruzzi A, Albani F, Riva R. Oxcarbazepine: pharmacokinetic interactions and their clinical relevance. Epilepsia 1994; 35 Suppl. 3: 14-9
95. Knutt H. Phenobarbital. Interactions with other drugs. In: Levy R, Mattson R, Meldrum B, editors. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995: 389-99
96. Koup JR, Gibaldi M, McNamara P, et al. Interaction of chloramphenicol with phenytoin and phenobarbital. Clin Pharmacol Ther 1978; 24: 571-5
97. Cucinell SA, Conney AH, Sansur MS, et al. Drug interactions in man. Lowering effect of phenobarbital on plasma levels of bishydroxycoumarin (dicumarol) and diphenylhydantoin (dilantin). Clin Pharmacol Ther 1965; 6: 420-9
98. Conney AH. Pharmacological implications of microsomal enzyme induction. Pharmacol Rev 1967; 19: 317-66
99. Gay PE, Madsen JA. Interaction between phenobarbital and thioridazine. Neurology 1983; 33: 1631-2
100. Hayduckewyck D, Rodin EA. Effect of phenothiazine on serum antiepileptic drug concentration in epileptic patients with seizure disorder. Ther Drug Monit 1985; 7: 401-5
101. Mattson RH, Gallager BB, Reynolds EH, et al. Folate therapy in epilepsy: a controlled study. Arch Neurol 1973; 29: 78-81
102. Hansson O, Sillanpaa M. Pyridoxine and serum concentrations of phenytoin and phenobarbitone. Lancet 1976; 1: 256
103. Vesell ES, Page JG. Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man. J Clin Invest 1969; 48: 2202-9
104. Stambaugh JE, Hemphill DM, Wainer IW, et al. A potentially toxic drug interaction between pethidine (meperidine) and phenobarbital. Lancet 1977; 1: 398-9
105. Brooks SM, Werk EE, Ackerman J, et al. Adverse effect of phenobarbital on corticosteroid metabolism in patients with bronchial asthma. N Engl J Med 1972; 286: 1125-8
106. Krasinski K, Kusmiesz H, Nelson JD. Pharmacologie interaction among chloramphenicol, phenytoin and phenobarbital. Pediatr Infect Dis 1982; 1: 232-5
107. Neuvonen PJ, Penttilä O, Lehtovaara R, et al. Effect of antiepileptic drugs on the elimination of various tetracycline derivatives. Eur J Clin Pharmacol 1975; 9: 147-54
108. Somogyi A, Gugler R. Drug interactions with cimetidine. Clin Pharmacokinet 1982; 7: 23-41
109. Goss JL, Dickhaus DW. Increased bislivdroxycoumarin requirements in patients receiving phenobarbital. N Engl J Med 1965; 273: 1094-5
110. Rutledge DR, Pieper JA, Mirvis DM. Effects of chronic phenobarbital on verapamil disposition in humans. J Pharmacol Exp Ther 1988; 246: 7-11
111. Carstensen H, Jacobsen N, Dieperink H. Interaction between cyclosporin and phenobarbitone. Br J Clin Pharmacol 1986; 21: 550-1
112. Braithwaite RA, Flanagan RA, Richens A. Steady state plasma nortriptyline concentration in epileptic patients. Br J Clin Pharmacol 1975; 2: 469-71
113. Spina E, Avenoso A, Campo GM. Phenobarbital induces the 2-hydroxylation of desipramine. Ther Drug Mon 1996; 18: 60-4
114. Linnoila M, Viukari M, Vaisanen K, et al. Effects of anticonvulsants on plasma haloperidol and thioridazine levels. Am J Psychiatry 1980; 137: 819-21
115. Hancock KW, Levell MJ. Primidone/dexamethasone interaction [letter]. Lancet 1978; 2: 97-8
116. Brooks PM, Buchanan WW, Grove M, et al. Effects of enzyme-induction on metabolism of prednisolone. Clinical and laboratory sludy. Ann Rheum Dis 1976; 35: 339-43
117. Hempel E, Klinger W. Drug stimulated biotransformation of hormonal steroid contraceptives: clinical implications. Drugs 1976; 12: 442-8
118. Back DJ, Bates M, Bowden A, et al. The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy. Contraception 1980; 22: 495-503
119. Andreasen PB, Froland A, Skovsted L, et al. Diphenylhydantoin half-life in man and its inhibition by phenylbutazone: the role of genetic factors. Acta Med Scand 1973; 193: 561-4
120. Perucca E, Richens A. Drug interactions with phenytoin. Drugs 1981; 21: 120-37
121. Mohlholm Hansen J, Kampmann JP, Siersbaek-Nielsen K, et al. The effect of different sulfonamides on phenytoin metabolism in man. Acta Med Scand 1979; 624 Suppl. 1: 106-10
122. Kutt H. Phenytoin. Interactions with other drugs: clinical aspects. In: Levy R, Mattson R, Meldrum B, editors. Antiepileptic drugs. 4th ed. New York: Raven Press. 1995: 315-27
123. Kutt H, Winters W, McDowell F. Depression of parahydroxylation of diphenylhydantoin by antituberculous chemotherapy. Neurology 1966; 16: 594-602
124. Brennan RW, Deheija H, Kutt H, et al. Diphenylhydantoin intoxication attendant to slow inactivation of isoniazid. Neurology 1970; 20: 687-93
125. Blum RA, Wilton JH, Hilligros D, et al. Effect of fluconazole on disposition of phenytoin. Clin Pharmacol Ther 1991; 49: 420-5
126. Bourgoin B, Begaud B, Loiseau P. Interaction pharmacocinétique possible phénytoïne-miconazole. Therapie 1981; 36: 347-9
127. Rolan PE, Somogyi AA, Drew MJR, et al. Phenytoin intoxication during treatment with parenteral miconazole. BMJ 1983; 287: 1760
128. Rabinowicz AL, Hinton DR, Dyck P, et al. High-dose tamoxifen in treatment of brain tumors: interaction with antiepileptic drugs. Epilepsia 1995; 36: 513-5
129. Hetzel DJ, Bochner F, Hallpike JF, et al. Cimetidine interaction with phenyloin. BMJ 1981; 282: 1512
130. Neuvonen PJ, Tokola RA, Kaste M. Cimetidine-phenytoin interaction: effect on serum phenytoin concentration and antipyrine test. Eur J Clin Pharmacol 1981; 21: 215-20
131. Salem RB, Breland BD, Mishra SK, et al. Effect of cimetidine on phenytoin serum levels. Epilepsia 1983; 24: 284-8
132. Frigo GM, Lecchini S, Caravaggi M, et al. Reduction in phenytoin clearance caused by cimetidine. Eur J Clin Pharmacol 1983; 25: 135-7
133. Levine M, Jones MW, Sheppard I. Differential effect of cimetidine on serum concentrations of carbamazepine and phenytoin. Neurology 1985; 35: 562-5
134. Molholm Hansen J, Kristensen M, Skovsted L, et al. Dicoumarol-induced diphenylhydantoin intoxication. Lancet 1966; 2: 265-6
135. Skovsted L, Kristensen M, Molholm Hansen J, et al. The effect of different oral anticoagulants on diphenylhydantoin (DPH) and tolbutamide metabolism. Acta Med Scand 1976; 199: 513-5
136. McGovern B, Geer VR, Laraia PJ, et al. Possible interaction between amiodarone and phenytoin. Ann Intern Med 1984; 101: 650-1
137. Solomon H, Abrams WB. Interactions between digitoxin and other drugs in man. Am Heart J 1972; 83: 277-80
138. Riva R, Cerullo A, Albani F, et al. Ticlopidine impairs phenytoin clearance: a case report. Neurology 1996; 46: 1172-3
139. Kutt H, McDowell F. Management of epilepsy with diphenylhydantoin sodium. JAMA 1968; 203: 969-72
140. Rogers HJ, Haslam RA, Longstreth J, et al. Phenytoin intoxication during concurrent diazepam therapy. J Neurol Neurosurg Psychiatry 1977; 40: 890-5
141. Pisani F, Fazio A, Artesi C, et al. Elevation of plasma phenytoin by viloxazine in epileptic patients: a clinically significant drug interaction. J Neurol Neurosurg Psychiatry 1992; 55: 126-7
142. Garrettson LK, Perel JM, Dayton PG. Methylphenidate interaction with both anticonvulsants and ethyl biscoumacetate. JAMA 1969; 207: 2053-6
143. Kutt H. Interactions of antiepileptic drugs. Epilepsia 1975; 16: 393-402
144. Vincent FM. Phenothiazine-induced phenytoin intoxication. Ann Intern Med 1980; 93: 56-7
145. Perucca E, Richens A. Interaction between phenytoin and imipramine. Br J Clin Pharmacol 1977; 4: 485-6
146. Dorn JM. A case of phenytoin toxicity possibly precipitated by trazodone. J Clin Psychiatry 1986; 47: 89-90
147. Solomon HM, Schrogie JJ. The effect of phenyramidol on the metabolism of diphenylhydantoin. Clin Pharmacol Ther 1967; 8: 554-6
148. Pugh RNH, Geddes AM, Yeoman WB. Interaction of phenytoin with chlorpheniramine. Br J Clin Pharmacol 1975; 2: 173-5
149. Olesen OV. The influence of disulfiram and calcium carbimide on the serum diphenylhydantoin. Arch Neurol 1967; 16: 642-4
150. Geaney DP, Carver JG, Davies CL, et al. Pharmacokinetic investigation of the interaction of azapropazone with phenyloin. Br J Clin Pharmacol 1983; 15: 727-34
151. Kiorboe E. Phenytoin intoxication during treatment with anlabuse (disulfiram). Epilepsia 1966; 7: 246-9
152. Vesell ES, Passananti GT, Lee CH. Impairment of drug metabolism by disulfiram in man. Clin Pharmacol Ther 1971; 21: 785-92
153. Svendsen TL, Kristensen MB, Mohlson Hansen J, et al. The influence of disulfiram on the half life and metabolic clearance of diphenylhydantoin and tolbutamide in man. Eur J Clin Pharmacol 1976; 9: 739-41
154. Fincham RW, Wiley DE, Schottelius DD. Use of phenytoin serum levels in a case of status epilepticus. Neurology 1976; 26: 879-81
155. Kay L, Kampmann JP, Svendsen TL, et al. Influence of rifampin and isoniazid on the kinetics of phenytoin. Br J Clin Pharmacol 1985; 20: 323-6
156. Fincham RW, Schottelius DD. Decreased phenytoin levels in antineoplastic therapy. Ther Drug Monit 1979; 1: 277-83
157. Bollini P, Riva R, Albani FI, et al. Decreased phenytoin level during antineoplastic therapy, a case report. Epilepsia 1983; 24: 75-8
158. Sylvester RK, Lewis FB, Caldwell KC, et al. Impaired phenytoin bioavailability secondary to cisplatinum, vinblastine and bleomycin. Ther Drug Monit 1984; 6: 302-5
159. Carter BL, Garnett WR, Pellock JM, et al. Effects of antacids on phenytoin bioavailability. Ther Drug Monit 1981; 3: 333-40
160. Turck D, Largilliere C, Dupuis B, et al. Interaction entre le diazoxide et la phényloïne. Press Med 1986; 15: 31
161. Molholm Hansen J, Siersbaek-Nielsen K, Kristensen M, et al. Effect of diphenylhydantoin on the metabolism of dicoumarol in man. Acta Med Scand 1971; 189: 15-9
162. Nappi JM. Warfarin and phenytoin interaction. Ann Intern Med 1979; 90: 852
163. Data JL, Wilkinson GR, Nies AS. Interaction of quinidine with anticonvulsant drugs. N Engl J Med 1976; 294: 699-702
164. Aitio ML, Mansbury L, Tala E, et al. The effect of enzyme induction on the metabolism of disopyramide in man. Br J Clin Pharmacol 1981; 11: 279-86
165. Capewell S, Freestone S, Critchley JAJH, et al. Reduced felodipine bioavailabilily in patients taking anticonvulsants. Lancet 1988; 2: 480-2
166. Michelucci R, Cipolla G, Passarelli D, et al. Reduced plasma nisoldipine concentrations in phenytoin-treated patients with epilepsy. Epilepsia 1996; 37: 1107-10
167. Ahmad S. Renal insensitivity to furosemide caused by chronic anticonvulsant therapy. BMJ 1974; 3: 657-9
168. Freeman DJ, Laupacis A, Keown A, et al. Evaluation of cyclosporin-phenvloin interaction with observations on cyclosporin metabolites. Br J Clin Pharmacol 1984; 18: 887-93
169. McLelland J, Jack W. Phenytoin/dexamethasone interaction: a clinical problem [letter]. Lancet 1978; 1: 1096-7
170. Chalk JB, Ridgeway K, Brophy T, et al. Phenytoin impairs the bioavailability of dexamethasone in neurological and neurosurgical patients. J Neurol Neurosurg Psychiatry 1984; 47: 1087-90
171. Petereit LB, Meikle AW. Effectiveness of prednisolone during phenytoin therapy. Clin Pharmacol Ther 1977; 22: 912-6
172. Gram L. Pharmacokinetics of new antiepileptic drugs. Epilepsia 1996: 37 Suppl. 6: 12-6
173. Bopp BA, Nequist GE, Rodrigues AD. Role of the cytochrome P450 3A subfamily in the metabolism of [14C] tiagahine in human hepatic microsomes [abstract]. Epilepsia 1995; 36 Suppl. 3: 159
174. Thompson MS, Groes L, Schwietert HR, et al. An open label sequence listed two period crossover pharmacokinetic trial evalualing the possible interaction between tiagabine and erythromycin during multiple administration to healthy volunteers [abstract]. Epilepsia 1997; 38 Suppl. 3: 64
175. Gustavson L, Mengel HB. Pharmacokinetics of tiagabine, a gamma-aminobutyric acid-uptake inhibitor, in healthy subjects alter single and multiple doses. Epilepsia 1995; 36: 605-11
176. Mengel HB, Houston A, Back DJ. Tiagabine: evaluation of the risk of interaction with the oral contraceptive pill in female volunteers [abstract]. Epilepsia 1993; 34 Suppl. 2: 157
177. Mengel H, Jansen JA, Sommerville K, et al. Tiagabine: evaluation of the risk of interaction with theophylline, warfarin, digoxin, cimetidine, oral contraceptive, triazolam, or ethanol [abstract]. Epilepsia 1995; 36 Suppl. 3: 160
178. Liao S, Palmer M. Digoxin and topiramate drug interaction study in male volunteers [abstract]. Pharm Res 1993; 10 Suppl.: S405
179. Rosenfeld WE, Doose DR, Walker SA, et al. Effecte of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinylestradiol in patients with epilepsy. Epilcpsia 1997; 38: 317-23
180. Davies R, Peters DH, McTavish. Valproic acid: a reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1994; 47: 332-72
181. Garnett WR, Small RE, Pellock JM. Effects of three antacids on the bioavailabilily of valproic acid. Clin Pharm 1982; 1: 244-7
182. Grimaldi R, Lechini S, Crema F, et al. In vivo plasma protein binding interaction between valproic acid and naproxen. Eur J Drug Metab Pharmacokinet 1984; 9: 359-63
183. Abbott FS, Kassam J, Orr JM, et al. The effect of aspirin on valproic acid metabolism. Clin Pharmacol Ther 1986; 40: 94-100
184. Goulden KJ, Dooley JM, Camfield PR, et al Clinical valproate toxicity induced by acetylsalicylic acid. Neurology 1987; 37: 1392-4
185. Jonville AP, Gauchez AS, Autret E, et al. Interaction between isoniazid and valproate: a case of valproate overdosage. Eur J Clin Pharmacol 1991; 40: 197-8
186. Webster LK, Mihaly GW, Jones DB, et al. Effects of cimetidine and ranitidine on carbamazepine and sodium valproate pharmacokinetics. Eur J Clin Pharmacol 1984; 27: 341-3
187. Ishizaki T, Chiba K, Saito K, et al. The effects of neuroleptics thaloperidol and chlorproinazine) on the pharmacokinetics of valproic acid in schizophrenic patients. J Clin Psychopharmacol 1984: 4: 254-61
188. Crawford P, Chadwick D, Cleland P, et al. The lack of effect of sodium valproate on the pharmacokinetics of oral steroids. Contraception 1986; 33: 23-9
189. Rey E, Pons G, Olive G. Vigabatrin. Clinical pharmacokinetics. Clin Pharmacokinel 1992; 23: 267-78, 1993; 25: 433-43
190. Rey E, Pons G, Olive G. Vigabatrin. Clinical pharmacokinetics. Clin Pharmacokinel 1992; 23: 267-78, 1993; 25: 433-43
191. Bartoli A, Gatti G, Cipolla G, et al. Vigabatrin does not affect in vivo parameters of enzyme induction in humans. Epilepsia 1997; 38: 702-7